Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Clinical Trial

Official title:

Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02955355
• Other study ID #: 161505
• Secondary ID: 2016-000374-37
• Status: Completed
• Phase: Phase 3
• Start date: December 12, 2016
• Est. completion date: July 4, 2023

Study information

• Verified date: July 2023
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study. The main aim of the study is to evaluate side effects in the long-term treatment with HYQVIA/HyQvia. All participants will receive HYQVIA/HyQvia in the same way as they were receiving in study 161403. The dosing interval of HYQVIA/HyQvia can be adjusted after 12 weeks of treatment in study 161505 if the study doctor determines that it is safe to do so. Participants will visit the clinic within 1 week after the first and second dose of HYQVIA/HyQvia and then every 12 weeks for the duration of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: July 4, 2023
• Est. primary completion date: July 4, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Has completed Epoch 1 of Study 161403 without CIDP worsening.

2. If female of childbearing potential, the participant must have a negative pregnancy test at baseline and agree to employ adequate birth control measures (eg, birth control pills/patches, intrauterine device, or diaphragm or condom [for male partner] with spermicidal jelly or foam) throughout the course of the study.

Exclusion Criteria:

1. Participant has a serious medical condition such that the participant's safety or medical care would be impacted by participation in this Extension Study.

2. New medical condition that developed during participation in study 161403 that, in the judgment of the investigator, could increase risk to the participant or interfere with the evaluation of investigational medicinal product (IMP) and/or conduct of the study.

3. Participant is scheduled to participate in another non-Baxalta clinical study involving an IP or investigational device during the course of this study.

4. The participant is nursing or intends to begin nursing during the course of the study

5. Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study (with the exception of study 161403) involving an IP or investigational device during the course of this study.

6. The participant is a family member or employee of the investigator.

Related Conditions & MeSH terms

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy
• Polyradiculoneuropathy
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Intervention

Biological:
• HYQVIA
Participants will receive subcutaneous (SC) HYQVIA/HyQvia which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).

Locations

Country	Name	City	State
Argentina	Hosp.Britanico de Buenos Aires	Ciudad Autonoma Buenos Aires
Brazil	Instituto de Neurologia de Curitiba - Hospital Ecoville	Curitiba	Paraná
Canada	University of Alberta Hospital	Edmonton	Alberta
Canada	LHSC - University Hospital	London	Ontario
Canada	Toronto General Hospital, University Health Network	Toronto	Ontario
Colombia	Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia "IPS UNIVERSITARIA"	Medellin
Czechia	Fakultni nemocnice Ostrava	Ostrava	Poruba
Czechia	Fakultni nemocnice v Motole	Prague 5
Denmark	Århus Universitetshospital	Aarhus C
France	Groupe Hospitalier Pellegrin - Hôpital Pellegrin	Bordeaux Cedex	Gironde
France	Hopital Neurologique Pierre Wertheimer	Bron Cedex	Rhone
France	CHU de Nice	Nice	Alpes Maritimes
Germany	Universitaetsklinikum Leipzig AoeR	Leipzig	Sachsen
Greece	University Hospital of Patra	Patras
Italy	Azienda Ospedaliero Universitaria San Martino	Genova
Italy	Azienda Ospedaliera Universitaria Policlinico G. Martino	Messina
Italy	Fondazione Istituto Neurologico Casimiro Mondino	Pavia
Italy	Azienda Ospedaliero Universitaria Pisana	Pisa
Italy	Azienda Ospedaliero-Universitaria Santa Maria della Misericordia	Udine
Mexico	Instituto Nacional de Ciencias Médicas y Nutricion Dr. Salvador Zubiran	Mexico	Distrito Federal
Poland	Uniwersyteckie Centrum Kliniczne	Gdansk
Poland	Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego	Lódz
Poland	Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie	Lublin
Serbia	Clinical Center of Serbia	Belgrade
Serbia	Military Medical Academy	Belgrade
Serbia	Clinical Center Nis	Nis
Slovakia	Fakultna nemocnica Nitra	Nitra
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Turkey	Pamukkale Uni. Med. Fac.	Denizli
Turkey	Dokuz Eylul University Faculty of Medicine	Izmir
Turkey	Selcuk Universitesi Selcuklu Tip Fakultesi Hastanesi	Konya
Turkey	Celal Bayar University Medical Faculty	Manisa
United Kingdom	The Walton Centre	Liverpool	Merseyside
United Kingdom	King's College Hospital	London	Greater London
United States	Arizona Neuromuscular Research Center	Phoenix	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Baxalta now part of Shire	Takeda Development Center Americas, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  Canada,  Colombia,  Czechia,  Denmark,  France,  Germany,  Greece,  Italy,  Mexico,  Poland,  Serbia,  Slovakia,  Spain,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Experiencing any Treatment-Emergent Serious Adverse Events (SAEs) and/or Adverse Events (AEs), Regardless of Causality	Number of participants experiencing any treatment-emergent SAEs and/or AEs, regardless of causality will be assessed. An AE is defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) is defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome is fatal/results in death, is life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.	Throughout the study period of approximately 7 years
Primary	Number of Participants Experiencing Causally Related Serious Adverse Events (SAEs) and/or Adverse Events (AEs)	Number of participants experiencing causally related SAEs and/or AEs will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Participants with Serious and/or Non-Serious Adverse Reactions (ARs) plus Suspected Adverse Reactions (ARs)	Number of participants with serious and/or non-serious ARs plus suspected ARs will be assessed. An AR plus suspected AR is any AE that meets any of the following criteria: an AE considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration, or an AE that begins during infusion of IP or within 72 hours following the end of IP infusion, or an AE for which causality assessment is missing or indeterminate.	Throughout the study period of approximately 7 years
Primary	Rate of Adverse Events (AEs) that may be a Result of Immune-Mediated Responses	Rate of AEs that may be a result of immune-mediated response to either immunoglobulin, rHuPH20, or other factors such as allergic reactions, immune complex mediated reactions -local, Immune complex mediated reactions-systemic which will be expressed as the number of events per infusion and per participant-year will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Treatment-Emergent Serious Adverse Events (SAEs) and/or Adverse Events (AEs) Associated with Infusions, Regardless of Causality	Causality is a determination of whether there is a reasonable possibility that the IP is etiologically related to/associated with the AE. Number of treatment-emergent serious adverse events (SAEs) and/or adverse events (AEs) associated with infusions, regardless of causality will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Causally Related Serious Adverse Events (SAEs) and/or Adverse Events (AEs) Associated with Infusions	Number of causally related serious adverse events (SAEs) and/or adverse events (AEs) associated with infusions will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Adverse Events (AEs) Temporally Associated with Infusions	Number of AEs temporally associated with infusions defined as AEs occurring during or within 72 hours after completion of an infusion will be assessed.	During or within 72 hours after completion of an infusion
Primary	Number of Serious and/or Non-Serious Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Associated with Infusions	Number of serious and/or non-serious ARs plus suspected ARs associated with infusions will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Infusions Associated with One or More Systemic Adverse Events (AEs)	Number of infusions associated with 1 or more systemic AEs will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Infusions Associated with One or More Local Infusion Site Reactions	Number of infusions associated with 1 or more local infusion site reactions will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion was Interrupted or Stopped due to Intolerability and/or Adverse Events (AEs)	Number of infusions for which the infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs will be assessed.	Throughout the study period of approximately 7 years
Primary	Rates of Systemic and local Adverse Events (AEs), Regardless of Causality	Rates of systemic and local AEs, regardless of causality will be expressed as number of events per infusion, per participant, and per participant-year.	Throughout the study period of approximately 7 years
Primary	Rates of Causally Related Systemic and Local Adverse Events (AEs)	Rates of causally related systemic and local AEs, will be expressed as number of events per infusion, per participant, and per participant-year.	Throughout the study period of approximately 7 years
Primary	Rates of Systemic and Local Adverse Reactions (ARs) plus Suspected Adverse Reactions (ARs)	Rates of systemic and local adverse reactions (ARs) plus suspected ARs, will be expressed as number of events per infusion, per participant, and per participant-year.	Throughout the study period of approximately 7 years
Primary	Number of Participants with an Adverse Event (AE) that led to Discontinuation from Study	Number of participants with an adverse event (AE) that led to discontinuation from study will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Moderate or Severe Adverse Events (AEs) that may be a Result of Immune-Mediated Responses	Number of moderate or severe adverse events (AEs) that may be a result of immune-mediated responses will be assessed.	Throughout the study period of approximately 7 years
Primary	Rate per Infusion of Moderate or Severe Adverse Events (AEs) that may be a Result of Immune-Mediated Responses	Rate per infusion of moderate or severe adverse events (AEs) that may be a result of immune-mediated responses will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Participants Experiencing Treatment-Emergent Local Infusion Site Reactions	Number of participants experiencing treatment-emergent local infusion site reactions will be assessed. All local infusion site treatment-emergent AEs will be reported as adverse reactions.	Throughout the study period of approximately 7 years
Primary	Number of Participants with Treatment-Emergent with Local Tolerability Events	Number of participants with treatment-emergent with local tolerability events during the first 8 weeks of open-label extension study 161505 among participants originally randomized to placebo (no ramp up), versus during the 8 week-ramp-up period for participants originally randomized to HYQVIA in double-blind Study 161403 will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Participants in whom Infusion Rate was Reduced and/or the Infusion was Interrupted or Stopped due to Intolerability and/or Adverse Events (AEs)	Number of participants in whom infusion rate was reduced and/or the infusion was interrupted or stopped due to intolerability and/or AEs will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Participants with Local Infusion Reactions, as a Function of Dosing Interval, Infusion Rate per Site, and Infusion Volume per Site	Number of participants experiencing local infusion reactions, as a function of dosing interval, infusion rate per site, and infusion volume per site will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Participants whose Anti-Hyaluronidase Antibody Titers Rise by Greater Than or Equal (> or =) ( 4 Fold from the Original Baseline Value from Study 161403 Using Combined Data from Both Studies (161403 and 161505)	Number of participants whose anti-hyaluronidase antibody titers rise by > or = 4 fold from the original baseline value from study 161403 using combined data from both studies (161403 and 161505) will be assessed.	Throughout the study period of approximately 7 years
Primary	Incidence of Binding Antibodies to rHuPH20	Incidence of binding antibodies to rHuPH20 will be assessed.	Throughout the study period of approximately 7 years
Primary	Incidence of Neutralizing Antibodies to rHuPH20	Incidence of neutralizing antibodies to rHuPH20 will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Participants with a Decline of Anti-rHuPH20 Antibody Titers to the Antibody Titer Level at Baseline in Study 161403 or Study 161601 and/or to Less than (<)160 at the Study Completion or Early Discontinuation	Number of participants with a decline of anti-rHuPH20 antibody titers to the antibody titer level at baseline in Study 161403 or Study 161601 and/or to <160 at the study completion or early discontinuation will be assessed.	Throughout the study period of approximately 7 years
Primary	Number of Participants who have Greater than (>) 10,000 Titer of Binding Antibodies to rHuPH20: Neutralizing Antibodies and Cross Reactivity with Hyal-1,2 and 4	Number of participants who have >10,000 titer of binding antibodies to rHuPH20: neutralizing antibodies and cross reactivity with Hyal-1,2 and 4 will be assessed.	Throughout the study period of approximately 7 years

External Links

•   To obtain more information on the study, click here/on this link